|
Loading...
Loading...
|
US Pharm. 2008;33(7):HS-16.
Attendees at a meeting of the American Association for Cancer Research learned that while the results of a study conducted at Rutgers University in New Brunswick, NJ, showed that atorva statin (Lipitor) and celecoxib (Celebrex) individually slowed tumor progression from androgen-dependent to androgen-independent status, the two drugs combined had additive growth-inhibiting activity compared with either drug alone.
According to Xi Zheng, PhD, of Rutgers, study results showed that the combination of the two drugs represented "a viable prevention strategy to stop the progression of prostate cancer to androgen-independent status, which is more aggressive and currently has limited therapeutic options."
To comment on this article, contact
rdavidson@jobson.com.
|
Loading...
Loading...
|
|
U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date,
authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings,
including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations,
long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students,
other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn
Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE)
as a provider of continuing pharmacy education.
Copyright © 2000 - 2013 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.
|